Press Releases

Here is an up-to-date collection of any information given to the press. It’s a big collection, so try not to look at it all in one sitting.

Press Releases

 
Press Releases
Date Title and Summary View
Sep 1, 2015 BOSTON, Sept. 1, 2015 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), a biopharmaceutical company focused on the development and commercialization of new cancer immuno-therapies, today announced the publication of a preclinical study in Cancer Research, a journal of the American Association for Cancer Research, demonstrating the prefere...
PDF
Aug 10, 2015 BOSTON, Aug. 10, 2015 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced financial results for the second quarter ended June 30, 2015, and provided an update on the company's recent activities. "ZIOPHARM continues to make important headway, both in the lab and clinic, in the development of our novel gene and adoptive cell...
PDF
Jul 24, 2015 BOSTON, July 24, 2015 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for Ad-RTS-hIL-12 + veledimex in the treatment of patients with ma...
PDF
Jun 2, 2015 BOSTON, June 2, 2015 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced that Caesar J. Belbel, Executive Vice President, Chief Legal Officer and Secretary, has been appointed to the added role of Chief Operating Officer, eff...
PDF
May 7, 2015 BOSTON, May 7, 2015 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced financial results for the first quarter ended March 31, 2015, and provided an update on the company's recent activities. "Through new and existing partnerships with Intrexon and Merck Serono, ZIOPHARM now links a set of immunotherapy programs and techn...
PDF
May 7, 2015 BOSTON, May 7, 2015 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced the appointment of Laurence J. N. Cooper, M.D., Ph.D., to the role of Chief Executive Officer, effective immediately. Dr. Cooper brings extensive experience in pioneering the development of adoptive cellular therapies in the field of oncology and translati...
PDF
May 5, 2015 BOSTON, May 5, 2015 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced the initiation of a Phase 1 study of Ad-RTS-hIL-12 + veledimex in patients with recurrent or progressive glioblastoma or Grade III malignant glioma, a fo...
PDF
Apr 27, 2015 BOSTON, April 27, 2015 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced the initiation of a Phase 1b/2 study of Ad-RTS-hIL-12 + veledimex following standard chemotherapy for the treatment of patients with locally advanced ...
PDF
Mar 30, 2015 BOSTON and GERMANTOWN, Md., March 30, 2015 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) and Intrexon Corporation (NYSE:XON) today announced their oncology programs will be strengthened through Intrexon's new global collaboration focused exclusively on novel chimeric antigen receptor T-cell (CAR-T) products with Merck Serono, the biopha...
PDF
Feb 26, 2015 BOSTON, Feb. 26, 2015 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced financial results for the fourth quarter and full year ended December 31, 2014, and provided an update on the company's recent activities. "ZIOPHARM has achieved remarkable progress in the last several quarters, uniting a number of technologies and d...
PDF
Page:
1
... NextLast